Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial
Open Access
- 9 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 18 (1), 1-16
- https://doi.org/10.1186/s12916-020-01542-9
Abstract
Chronic kidney disease with metabolic acidosis is common in older people, but the effectiveness of oral sodium bicarbonate therapy in this group is unclear. We tested whether oral sodium bicarbonate provides net health benefit for older people with advanced chronic kidney disease and serum bicarbonate concentrations < 22 mmol/L. Pragmatic multicentre, parallel group, double-blind, placebo-controlled randomised trial. We recruited adults aged ≥ 60 years with estimated glomerular filtration rate of < 30 mL/min/1.73 m2, not receiving dialysis, with serum bicarbonate concentration < 22 mmol/L, from 27 nephrology and geriatric medicine departments in the UK. Participants received oral sodium bicarbonate (up to 3 g/day) or matching placebo given for up to 2 years, randomised in a 1:1 ratio. The primary outcome was between-group difference in the Short Physical Performance Battery (SPPB) at 12 months, adjusted for baseline values, analysed by intention to treat. Secondary outcomes included generic and disease-specific quality of life (EQ-5D and KDQoL tools), anthropometry, renal function, walk distance, blood pressure, bone and vascular health markers, and incremental cost per quality-adjusted life year gained. We randomised 300 participants between May 2013 and February 2017, mean age 74 years, 86 (29%) female. At 12 months, 116/152 (76%) participants allocated to bicarbonate and 104/148 (70%) allocated to placebo were assessed; primary outcome data were available for 187 participants. We found no significant treatment effect for the SPPB: bicarbonate arm 8.3 (SD 2.5) points, placebo arm 8.8 (SD 2.2) and adjusted treatment effect − 0.4 (95% CI − 0.9 to 0.1, p = 0.15). We found no significant treatment effect for glomerular filtration rate (0.6 mL/min/1.73 m2, 95% CI − 0.8 to 2.0, p = 0.39). The bicarbonate arm showed higher costs and lower quality of life as measured by the EQ-5D-3L tool over 1 year (£564 [95% CI £88 to £1154]); placebo dominated bicarbonate under all sensitivity analyses. Adverse events were more frequent in those randomised to bicarbonate (457 versus 400). Oral sodium bicarbonate did not improve physical function or renal function, increased adverse events and is unlikely to be cost-effective for use by the UK NHS for this patient group. European Clinical Trials Database (2011-005271-16) and ISRCTN09486651; registered 17 February 2012.Funding Information
- National Institute for Health Research (10/71/01)
This publication has 32 references indexed in Scilit:
- Effects of Treatment of Metabolic Acidosis in CKDClinical Journal of the American Society of Nephrology, 2019
- Oral Bicarbonate Therapy in Non-Haemodialysis Dependent Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled TrialsJournal of Clinical Medicine, 2019
- Serum Bicarbonate and Bone Mineral Density in US AdultsAmerican Journal of Kidney Diseases, 2015
- Association of Serum Bicarbonate with Incident Functional Limitation in Older AdultsClinical Journal of the American Society of Nephrology, 2014
- Serum Bicarbonate Concentrations and Kidney Disease Progression in Community-Living Elders: The Health, Aging, and Body Composition (Health ABC) StudyAmerican Journal of Kidney Diseases, 2014
- Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) StudyAmerican Journal of Kidney Diseases, 2013
- Association of Serum Bicarbonate Levels With Gait Speed and Quadriceps Strength in Older AdultsAmerican Journal of Kidney Diseases, 2011
- Serum Bicarbonate and Long-term Outcomes in CKDAmerican Journal of Kidney Diseases, 2010
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney diseaseKidney International, 2004